MDXH
MDxHealth S.A. (MDXH) PESTLE Analysis Analysis (2026)
No material changes this month.
Overall Score
Political
No major political or regulatory catalyst is evident in the current data.
The company remains exposed to general healthcare policy and reimbursement risk, but no new policy developments were reported this month.
Economic
Valuation remains inexpensive on a sales basis at 1.26x EV/Sales TTM, but profitability is still negative with a -0.32 net margin.
Liquidity is only modest, with a current ratio of 1.08 and cash ratio of 0.59, while free cash flow remains negative on a yield basis.
Social
No new demand or adoption trend was reported in recent news.
The business still depends on sustained clinical and customer acceptance, but there is no fresh evidence of a meaningful shift in end-market sentiment.
Technological
R&D intensity remains meaningful at 15.9% of revenue, supporting ongoing product development.
There is no new product launch or technology milestone in the latest news to change the outlook materially.
Legal
No new litigation, compliance, or patent-related developments were reported this month.
Legal risk remains tied to the healthcare and diagnostics environment, but there is no fresh catalyst indicating a change.
Environmental
No material environmental developments were reported in the latest data.
Environmental exposure appears limited relative to other PESTLE factors, with no new ESG-related catalyst this month.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on MDxHealth S.A.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.